

Treatment of urinary incontinence and related disorders, by increasing intracellular cyclic adenosine monophosphate concentration, e.g. using adenylyl cyclase stimulant such as forskolin

Publication number: DE19935209 (A1)

Publication date: 2001-02-08

Inventor(s): TRUSS MICHAEL CARSTEN [DE]; STIEF CHRISTIAN G [DE]; JONAS UDO [DE]; UECKERT STEFAN [DE]; BECKER ARMIN J [DE]; FORSSMANN WOLF-GEORG [DE]

Applicant(s): TRUSS MICHAEL C [DE]; UECKERT STEFAN [DE]

Classification:

- international: A61K31/00; A61K31/352; A61K31/4375; A61K31/00; A61K31/352; A61K31/4353; (IPC1-7): A61K31/495; A61K31/35

- European: A61K31/00; A61K31/352; A61K31/4375

Application number: DE19991035209 19990727

Priority number(s): DE19991035209 19990727

Abstract of DE 19935209 (A1)

Use of intracellular cyclic adenosine monophosphate (cAMP) concentration increasing agents (I) for treating urge symptoms, urge incontinence, pollakiuria, nycturia and detrusor muscle instability, where (I) is a cellular adenylyl cyclase stimulant, modulator of binding to beta 1-, beta 2- or beta 3-adrenoceptors of the urinary bladder musculature or a cellular cAMP hydrolyzing phosphodiesterase inhibitor. The use of intracellular cyclic adenosine monophosphate (cAMP) concentration increasing agents (I) is claimed for treating urge symptoms, urge incontinence, pollakiuria, nycturia and detrusor muscle instability, where (I) is selected from (a) cellular adenylyl cyclase stimulants, (b) modulators of binding to beta 1-, beta 2- or beta 3-adrenoceptors of the urinary bladder musculature and (c) cellular cAMP hydrolyzing phosphodiesterase inhibitors.; Alternatively (I) is replaced by cAMP analogs (II) which stimulate the phosphorylating activity of cellular cAMP-binding protein kinases and thus reduce the cytosolic calcium ion concentration. An Independent claim is included for pharmaceutical preparations comprising combinations of (I) (a)-(c).

Data supplied from the **esp@cenet** database — Worldwide